Journal article
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
Abstract
Purpose To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen …
Authors
Azad AA; Beardsley EK; Hotte SJ; Ellard SL; Klotz L; Chin J; Kollmannsberger C; Mukherjee SD; Chi KN
Journal
Investigational New Drugs, Vol. 32, No. 4, pp. 746–752
Publisher
Springer Nature
Publication Date
August 2014
DOI
10.1007/s10637-014-0091-8
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleNitrilesPiperidinesProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantProtein Kinase InhibitorsQuinazolinesTosyl CompoundsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2